Search

ANTIL® 500 Pellets – A versatile rheology modifier with outstanding thickening properties

2017.4.25.

Evonik introduces ANTIL® 500 Pellets, a novel and versatile rheology modifier for various cleansing formulations.

As an innovative hydrophilic polymer, ANTIL® 500 Pellets enables a significant reduction of the active surfactant level in standard cleansing formulations. In addition, the extraordinary efficiency and high flexibility of ANTIL® 500 Pellets facilitate the thickening of challenging surfactant systems, such as sulfate-free formulas, effectively supporting the trend for milder cleansing in personal care.

The 100% active, preservative-free solid is clearly soluble in water and processable at room temperature. Furthermore, ANTIL® 500 Pellets is stable against hydrolysis and effective over a wide pH range. The thickening agent provides a rich formulation texture with Newtonian flow behavior but without changing the foaming characteristics, which is essential for fulfilling the consumers’ sensorial expectations of personal cleansing products.

ANTIL® 500 Pellets is your innovative choice for the development of mild and cost-effective surfactant-based skin and hair care formulations.

Contact

Mari Sugata

Contact

  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12,7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

  • About Nutrition & Care

    The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
    €4.3 billion in 2016.

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.